EUVIMED · CrossrefJournal
Dermatology and Therapy
ISSN 2193-8210 · Springer Science and Business Media LLC
Latest articles
Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
Neurophysiological and Sleep-Related Effects of a Cosmetic Shampoo and Conditioner Regimen in Adults with Scalp Discomfort: A Pilot Study
Pyoderma Gangrenosum in Patients with Palmoplantar Pustulosis Treated with Brodalumab: A Case Series
Adjunctive Panthenol-Enriched Balm during Oral Isotretinoin: Hydration and Barrier Outcomes
Defining “Moderate” Psoriasis: A Targeted Review of the Medical Literature and Published Treatment Guidelines
Exosome + PRP Combination Therapy as a Novel Biological Treatment for Acute Facial and Cervical Burns: A Clinical Case Report
Adjunctive Efficacy of a Ceramide-Containing Repair and Moisturizing Cream in the Management of Mild-to-Moderate Plaque Psoriasis
Forty-Eight-Week Real-World Outcomes of Ritlecitinib in Alopecia Areata: Delayed Responses and Predictive Value of Change in SALT Score at Week 24
Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis
Dermatologist or AI? Patient Preferences in Skin Assessment
Long-Term Outcomes of Image-Guided Superficial Radiation Therapy for Stage I–II Nonmelanoma Skin Cancer: A Real-World Retrospective Cohort Study
Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study
Self-Reported Disease Severity and Treatment Experience among Individuals Reporting Healthcare Professional-Diagnosed Chronic Hand Eczema: Findings from the Cross-Sectional CHECK-US Study
Real-World Effectiveness of Risankizumab for Moderate-to-Severe Plaque Psoriasis by Sub-populations: Interim Analysis from VALUE at 37 Months
Treat-to-Target in Atopic Dermatitis: An Italian Survey and Expert Opinion on Clinical Practice and Unmet Needs
Perimenopause and Menopause: Estrogen-Deficient Skin and Impaired Quality of Life—Dermal Aging a Visible Mirror Reflecting Internal Aging and Health
How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication
Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities
Exploring How Healthcare Professionals Diagnose and Manage Vitiligo: Global VALIANT Study Findings and Recommendations
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis
Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs
JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”
Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
EUVIMED